1. Generics Bulletin
  2. >>Business
  3. >>Earnings

API gains boost Ipca’s sales

A 27% rise in turnover from active pharmaceutical ingredients (APIs) contributed to Ipca Laboratories increasing its group turnover by just over a fifth to Rs8.68 billion (US$121 million) in its financial first quarter ended 30 June 2018. Exports of APIs climbed by 17% to Rs1.58 billion, while the Indian company’s domestic sales of bulk drugs shot up by two-thirds to Rs600 million (see Figure 1).

A 27% rise in turnover from active pharmaceutical ingredients (APIs) contributed to Ipca Laboratories increasing its group turnover by just over a fifth to Rs8.68 billion (US$121 million) in its financial first quarter ended 30 June 2018. Exports of APIs climbed by 17% to Rs1.58 billion, while the Indian company’s domestic sales of bulk drugs shot up by two-thirds to Rs600 million (see Figure 1).

India was the driving force behind Ipca’s total Formulations sales advancing by 18% to Rs6.25 billion. Domestic sales ahead by...

Welcome to Generics Bulletin

Create an account to read this article

Already a subscriber?

More from Earnings

Krka Passes €1bn Threshold In Just Six Months

 
• By Dean Rudge

Krka has reported its strongest-ever half-year results, surpassing €1bn in sales and growing EBITDA by 8%. Solid performance across most regions, particularly Eastern and Central Europe, supported stable margins and a positive full-year outlook.

Stelara Biosimilar Sees Stada’s Specialty Sales Start Strong In Q1

 
• By Dave Wallace

Stada’s Specialty division was boosted by the firm’s launch last year of a European Stelara biosimilar, even as generics growth remained muted in Q1.

Glenmark Adamant FDA Monroe Site Reinspection Could Happen ‘Any Time’

 
• By Dean Rudge

A weak second half in Glenmark’s India business during the firm’s 2025 financial year took the gloss off its earnings somewhat for the year. However, Glenmark is plotting several avenues to return to growth, in both of its core business regions: India and the US.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

More from Business

Krka Passes €1bn Threshold In Just Six Months

 
• By Dean Rudge

Krka has reported its strongest-ever half-year results, surpassing €1bn in sales and growing EBITDA by 8%. Solid performance across most regions, particularly Eastern and Central Europe, supported stable margins and a positive full-year outlook.

Kirsty Gives Biocon A First Interchangeable US Insulin Aspart Biosimilar

 
• By Dave Wallace

After years of waiting, Biocon Biologics has finally snagged US FDA approval for its insulin aspart biosimilar – along with a first designation of interchangeability. However, Sanofi’s Merilog version is already approved as a rival to Novo Nordisk’s Novolog.

Room For Improvement? EU Industry Prepares Feedback For SPC Manufacturing Waiver Review

 
• By Dave Wallace

As the European Commission prepares a formal evaluation of the SPC manufacturing waiver, the generics and biosimilars industry is getting ready to provide detailed feedback on what works – and what doesn’t. At Medicines for Europe’s legal affairs conference, delegates heard the latest updates.